Search Videos and More
News
Dana-Farber Research Publication 11.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Document
Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.
Symposium
Research Updates - Metastatic Breast Cancer
In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.
News
Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
News
Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy
MatchMiner shortens time to identify appropriate precision medicine trials for individual patients
News
Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain
New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.
News
Dana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine
Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.
News
Kornelia Polyak Wins Prestigious American Cancer Society Award
Kornelia Polyak, MD, PhD, a breast cancer researcher at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School is the recipient of the American Cancer Society’s prestigious Research Professor Award.
Document
Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.Symposium Highlights 75 Years of Dana-Farber Science
Document
Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer
The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.